Tom Wilemon Archive — Page 23 of 40

March 12, 2020

Triple-negative breast cancer drug therapy shows promise

Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.

By Tom Wilemon
March 12, 2020

VICC’s Knoop elected to Oncology Nursing Society board of directors

Teresa Knoop, MSN, RN, assistant director of Clinical Operations for the Clinical Trials Office at Vanderbilt-Ingram Cancer Center (VICC), has been elected to the board of directors of the Oncology Nursing Society.

By Tom Wilemon
March 5, 2020

Das lands support for neuroendocrine tumor research

Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.

By Tom Wilemon
Dona Potter was treated with a new immunotherapy that entails re-engineering a patient’s T cells to target cancer.
February 27, 2020

Patient’s cancer treatment includes new immunotherapy

Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.

By Tom Wilemon
February 20, 2020

Symposium to focus on stem cell transplant, cellular therapies

New therapies that re-engineer patients’ T-cells to target cancer and advances in stem cell transplantations that make it easier for patients to be matched with donors are among the topics at an upcoming symposium.

By Tom Wilemon
February 13, 2020

Advocacy group’s gift boosts lung cancer research efforts

An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.

By Tom Wilemon